Drug Profile
BIIB 068
Alternative Names: BIIB068Latest Information Update: 28 Aug 2019
Price :
$50
*
At a glance
- Originator Biogen
- Class
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Systemic lupus erythematosus
Most Recent Events
- 28 Aug 2019 No recent reports of development identified for phase-I development in Systemic-lupus-erythematosus in USA (PO, Tablet)
- 01 Dec 2016 Biogen completes a phase I trial in Systemic lupus erythematosus in USA (PO) (NCT02829541)
- 25 Jul 2016 Phase-I clinical trials in Systemic lupus erythematosus in USA (PO) (NCT02829541)